Del-1 gene therapy - Valentis

Drug Profile

Del-1 gene therapy - Valentis

Alternative Names: DELTAVASC; VLTS 589

Latest Information Update: 21 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valentis
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 21 May 2007 Discontinued - Phase-II for Peripheral arterial disorders in USA (IM)
  • 21 May 2007 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
  • 21 Dec 2005 Data presented at the 78th Scientific Sessions of the American Heart Association (AHA-2005) have been added to the Vascular disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top